BeiGene, Ltd.
BGNE
Rang in Aktien
#1194
BeiGene, Ltd. is a global biotechnology enterprise that operates across the... BeiGene, Ltd. is a global biotechnology enterprise that operates across the entire pharmaceutical value chain, encompassing the research, development, production, and worldwide commercialization of diverse therapeutic agents. The company's commercially available product lineup includes several important medicines: BRUKINSA, an agent used for relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab, prescribed for R/R classical Hodgkin's lymphoma; REVLIMID, indicated for multiple myeloma; VIDAZA, which addresses myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA, a treatment for giant cell tumor of bone; BLINCYTO, for acute lymphoblastic leukemia; KYPROLIS, another therapy for R/R multiple myeloma; SYLVANT, targeting idiopathic multicentric Castleman disease; QARZIBA, for neuroblastoma; Pamiparib, applicable to various solid tumors; and Pobevcy, indicated for metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). Within its robust clinical development pipeline, BeiGene is actively advancing numerous investigational compounds. Key candidates include Zanubrutinib, a BTK inhibitor designed to combat lymphomas; Tislelizumab, an anti-PD-1 antibody under investigation for a spectrum of solid and hematological cancers; Lifirafenib and BGB-3245, both in trials for melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor targeting NSCLC, melanoma, and other solid tumors. Further expanding its clinical assets are BGB-A333, a PD-L1 inhibitor for diverse solid tumors; Ociperlimab, a TIGIT inhibitor also aimed at various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor for mature B-cell malignancies; BGB-A445, an OX40 agonist antibody for solid tumors; Zanidatamab, a bispecific HER2 inhibitor addressing breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor for a range of solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. BeiGene has also established strategic alliances with prominent industry partners, including Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. The company, incorporated in 2010, maintains its corporate headquarters in Cambridge, Massachusetts.
Aktienkurs
$184.00
Zuletzt synchronisiert: 2025-01-02
Marktkapitalisierung
$19.28B
Veränderung (1 Tag)
-0.38%
Veränderung (1 Jahr)
0.00%
Land
US
Handel BeiGene, Ltd. (BGNE)
Kategorie
Healthcare
Gewinn für BeiGene, Ltd. (BGNE)
Gewinn im Jun 2026 TTM: $868.08M
Laut den aktuellen Finanzberichten von BeiGene, Ltd. betragen die aktuellen Gewinne des Unternehmens $868.08M. Im Jahr 2023 erzielte das Unternehmen einen Gewinn von $-825.84M, eine Steigerung gegenüber dem Gewinn im Jahr 2022, der $-1.96B betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von BeiGene, Ltd. von 2013 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $868.08M | -262.87% |
| 2024 | $-533.00M | -35.46% |
| 2023 | $-825.84M | -57.89% |
| 2022 | $-1.96B | 36.32% |
| 2021 | $-1.44B | -11.10% |
| 2020 | $-1.62B | 71.49% |
| 2019 | $-943.59M | 36.79% |
| 2018 | $-689.83M | 657.52% |
| 2017 | $-91.06M | -23.58% |
| 2016 | $-119.16M | 108.68% |
| 2015 | $-57.10M | 207.89% |
| 2014 | $-18.55M | 134.94% |
| 2013 | $-7.89M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $5.27B | 507.65% |
US
|
|
| $-3.09B | -455.61% |
US
|
|
| $-4.02B | -562.65% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 124.71% |
NL
|
